The DOI matches its Crossref record; 49 of the 52 references it cites were found in a registry or an index.
Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis
Open accessPublished version of a preprint
Abstract
Recently emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants may pose a threat to immunity. A systematic landscape of neutralizing antibodies against emerging variants is needed. We systematically searched for studies that evaluated neutralizing antibody titers induced by previous infection or vaccination against SARS-CoV-2 variants and collected individual data. We identified 106 studies meeting the eligibility criteria. Lineage B.1.351 (beta), P.1 (gamma) and B.1.617.2 (delta) significantly escaped natural infection–mediated neutralization, with an average of 4.1-fold (95% confidence interval [CI]: 3.6–4.7-fold), 1.8-fold (1.4–2.4-fold), and 3.2-fold (2.4–4.1-fold) reduction in live virus neutralization assay, while neutralizing titers against B.1.1.7 (alpha) decreased slightly (1.4-fold [95% CI: 1.2–1.6-fold]). Serum from vaccinees also led to significant reductions in neutralization of B.1.351 across different platforms, with an average of 7.1-fold (95% CI: 5.5–9.0-fold) for nonreplicating vector platform, 4.1-fold (3.7–4.4-fold) for messenger RNA platform, and 2.5-fold (1.7–2.9-fold) for protein subunit platform. Neutralizing antibody levels induced by messenger RNA vaccines against SARS-CoV-2 variants were similar to, or higher, than that derived from naturally infected individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Alpha variant is susceptible to neutralization by most neutralizing mAbs as well as by most plasma samples from previously infected persons 97,102,121,149,159,[203][204][205][206] (fIg.5).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [97]
In the citing paper
“The Alpha variant has displayed 3-fold to 10-fold reduced susceptibility to approximately 15% of plasma samples from recipients of an authorized mRNA vaccine 97,102,121,148,149,152,159,204,208,209 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [97]
In the citing paper
“Of plasma samples from persons receiving one of the two authorized mRNA vaccines, about 60% had 3-fold to 10-fold and 5% had >10-fold reduced neutralizing activity 97,103,117,167,217,230 (fIg.5).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [97]
In the citing paper
“Of convalescent plasma samples obtained from persons infected with early pandemic variants or with the Alpha variant, about 20% had 3-fold to 10-fold and 10% had >10-fold reduced neutralizing activity 97,103,117,203,217,228,229 (fIg.5).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [97]
In the citing paper
“Of plasma samples obtained from persons receiving one of the mRNA vaccines, 45% had 3-fold to 10-fold and 30% had >10-fold reduced Beta variant neutralizing activity 97,104,117,121,151,204,208,209,222,223 (fIg.5).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [97]
In the citing paper
“The Beta variant has displayed 3-fold to 10-fold reduced susceptibility to 46% and >10-fold reduced susceptibility to 22% of convalescent plasma samples compared with early pandemic variants 97,101,104,121,124,203,204,[218][219][220] (fIg.5).”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [97]
Citations
Cites
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956
Data, disease and diplomacy: GISAID's innovative contribution to global health
Elbe, S., & Buckland‐Merrett, G. (2017) · Global Challenges · doi:10.1002/gch2.1018 · Cited by 1,928
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678
Flagged first, then by citations
3 of the 52 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–113 of 113
COVID-19 in renal replacement therapy patients: an overview of current data and future challenges
Biedunkiewicz, B., Dębska-Ślizień, A. M., & Tylicki, L. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16336 · Cited by 2
COVID-19 vaccine insights: The news beyond the headlines
Kiley (2022) · The Journal of Family Practice · doi:10.12788/jfp.0486
Lu, W., Zheng, N., Chen, X., Sun, R., Dong, J., Ge, S., Deng, X., & Yu, H. (2022) · medRxiv · doi:10.1101/2022.12.15.22283503
Self-citationRole of cellular fatty acids in combating the corona virus
Saxena, A., & Tiwari, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95582-9.00010-3
Wang, S., Guirakhoo, F., Periasamy, S., Ryan, V., Wiggins, J., Subramani, C., Thibodeaux, B. A., Sahni, J., Hellerstein, M. S., Kuzmina, N. A., et al. (2023) · Vaccines · doi:10.3390/vaccines12010040
“All COVID-19 vaccines incorporate the spike glycoprotein (S) of SARS-CoV-2 or its receptor-binding domain (RBD) as the key immunogens to elicit neutralizing antibodies crucial for protection [2–5].”
BackgroundChawansuntati, K., Sakkhachornphop, S., Hongjaisee, S., Freeouf, S., Sripan, P., Nusartsang, N., Chaiwarith, R., Sudjaritruk, T., Supparatpinyo, K., & Wipasa, J. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100475
“The neutralizing activity in serum samples obtained from vaccinated or naturally infected individuals reduced remarkably [5 – 8].”
BackgroundEmergence of SARS-CoV-2 Omicron lineages shifted antibody-mediated protection curves
Pattinson, D., Petrie, J. G., Jester, P. J., Guan, L., King, J. P., Halfmann, P., Belongia, E. A., Nguyen, H. Q., Kawaoka, Y., & Neumann, G. (2025) · iScience · doi:10.1016/j.isci.2025.113386
Basile, K., Agius, J. E., Fong, W., McPhie, K. A., Fennel, M., Ko, D., Heuston, L., Lam, C., Arnott, A., Chen, S. C.-A., et al. (2025) · Viruses · doi:10.3390/v17091161 · Cited by 1
“In this study, we confirm a reduction in nAbT after BNT162b2 vaccination when challenged with the Beta VOC [49–51], and demonstrate a significant 4.4-fold reduction in nAbT against the Delta VOC.”
InfluentialAnti-spike Antibody Response to Natural SARS-CoV-2 Infection
Bražinová, A., Kotrbancová, M., Perzelova, J., Novakova, D., Sokolova, J., Krsakova, A., Majdán, M., Prnova, J., & Fulová, M. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-025-00331-1
“…[36], Antibody titres, assessed in studies by various methods, including ECLIA, were in vaccinated individuals generally higher, more uniform, and more strongly directed against the spike protein compared to the more variable and broader responses observed in naturally infected cohorts [37, 38].”
Kapłonek, P., Bertera, H. L., Lee, D. W., Cizmeci, D., Yu, W., Wu, K., Chalkias, S., Wahid, R., Edwards, D. K., Alter, G., et al. (2025) · medRxiv · doi:10.1101/2025.09.30.25336755
Xu, S., Li, J., Wang, H., Wang, F., Yin, Z., & Wang, Z. (2023) · Figshare · doi:10.6084/m9.figshare.22715433
Zeng, B., Gao, L., Zhou, Q. X., Yu, K., & Sun, F. (2022) · Figshare · doi:10.6084/m9.figshare.19845824
Ahmed, B., Bala, J. A., Hafiz, T. R., Aliyu, I. A., Kumurya, A. S., Badamasi, I. M., Saidu, H., Abbas, M. A., Kabuga, A. I., Abdullahi, A. S., et al. (2026) · Next research. · doi:10.1016/j.nexres.2026.101493
Metadata
- Authors
- Chen, X., Chen, Z., Azman, A. S., Sun, R., Lu, W., Zheng, N., Zhou, J., Wu, Q., Deng, X., Zhao, Z., Chen, X., Ge, S., Yang, J., Leung, D. T., & Yu, H.
- Affiliations
- Fudan University (CN)
- University of Geneva (CH)
- University of Utah (US)
- Corresponding author
- Yu, Hongjie
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-24
- Volume
- 74
- Issue
- 4
- Pages
- 734-742
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC9016754
- OpenAlex
- W3183560460
- Cited by
- 113
- References
- 52
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 7 · 2023: 20 · 2022: 52 · 2021: 23
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- National Science Fund for Distinguished Young Scholars (81525023)
- Program of Shanghai Academic Research Leader (18XD1400300)
- National Science and Technology Major Project (2018ZX10713001-007, 2017ZX10103009-005, 2018ZX10201001-010)
- National Institutes of Health (R01 AI135115)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2 variants, neutralizing antibodies, antibody escape, natural infection, COVID-19 vaccines, mRNA vaccines, vector vaccines, subunit vaccine, neutralization titers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
